Elmind Capital
Latest statistics and disclosures from Elmind Capital's latest quarterly 13F-HR filing:
- Central Index Key (CIK): 0002052213
Tip: Access up to 7 years of quarterly data
Positions held by Elmind Capital consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Elmind Capital
Elmind Capital holds 34 positions in its portfolio as reported in the March 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Cogent Biosciences (COGT) | 12.8 | $45M | 1.2M | 38.49 |
|
|
| Syndax Pharmaceuticals (SNDX) | 12.3 | $43M | 1.9M | 23.36 |
|
|
| Celldex Therapeutics Com New (CLDX) | 7.8 | $27M | 865k | 31.72 |
|
|
| Cytomx Therapeutics (CTMX) | 6.1 | $21M | 4.6M | 4.70 |
|
|
| Kalvista Pharmaceuticals (KALV) | 5.8 | $21M | 1.0M | 20.13 |
|
|
| Cg Oncology (CGON) | 5.6 | $20M | 292k | 67.68 |
|
|
| Vera Therapeutics Cl A (VERA) | 5.5 | $19M | 483k | 40.23 |
|
|
| Vaxcyte (PCVX) | 5.2 | $18M | 317k | 58.11 |
|
|
| Pharvaris N V (PHVS) | 3.8 | $13M | 476k | 28.25 |
|
|
| Tyra Biosciences (TYRA) | 3.8 | $13M | 350k | 38.30 |
|
|
| Beam Therapeutics (BEAM) | 3.2 | $11M | 476k | 23.83 |
|
|
| Miragen Therapeutics (VRDN) | 3.0 | $11M | 535k | 19.56 |
|
|
| BioCryst Pharmaceuticals (BCRX) | 2.7 | $9.5M | 1.0M | 9.52 |
|
|
| United Therapeutics Corporation (UTHR) | 2.5 | $8.9M | 15k | 592.98 |
|
|
| Cullinan Oncology (CGEM) | 2.1 | $7.5M | 530k | 14.21 |
|
|
| Nurix Therapeutics (NRIX) | 2.0 | $7.1M | 460k | 15.50 |
|
|
| Mbx Biosciences (MBX) | 1.8 | $6.3M | 211k | 29.85 |
|
|
| Krystal Biotech (KRYS) | 1.6 | $5.7M | 22k | 258.32 |
|
|
| Dbv Technologies S A Sponsored Ads (DBVT) | 1.6 | $5.5M | 265k | 20.89 |
|
|
| Relay Therapeutics (RLAY) | 1.5 | $5.3M | 537k | 9.95 |
|
|
| Travere Therapeutics (TVTX) | 1.5 | $5.3M | 178k | 29.71 |
|
|
| Protagonist Therapeutics (PTGX) | 1.1 | $4.0M | 38k | 105.40 |
|
|
| Urogen Pharma (URGN) | 1.1 | $4.0M | 220k | 17.98 |
|
|
| Alumis (ALMS) | 0.8 | $2.9M | 130k | 22.03 |
|
|
| BioMarin Pharmaceutical (BMRN) | 0.8 | $2.7M | 47k | 56.49 |
|
|
| Design Therapeutics (DSGN) | 0.6 | $2.2M | 208k | 10.64 |
|
|
| Apellis Pharmaceuticals (APLS) | 0.6 | $2.0M | 50k | 40.23 |
|
|
| Alector (ALEC) | 0.5 | $1.9M | 900k | 2.15 |
|
|
| Immunocore Hldgs Ads (IMCR) | 0.5 | $1.8M | 58k | 30.15 |
|
|
| Amylyx Pharmaceuticals (AMLX) | 0.4 | $1.6M | 112k | 13.90 |
|
|
| Engene Holdings (ENGN) | 0.4 | $1.4M | 210k | 6.81 |
|
|
| Wave Life Sciences SHS (WVE) | 0.4 | $1.3M | 178k | 7.25 |
|
|
| Supernus Pharmaceuticals (SUPN) | 0.3 | $1.0M | 20k | 51.69 |
|
|
| Edgewise Therapeutics (EWTX) | 0.1 | $315k | 10k | 31.50 |
|
Past Filings by Elmind Capital
SEC 13F filings are viewable for Elmind Capital going back to 2026
- Elmind Capital 2026 Q1 filed May 15, 2026